Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZT6JR)

• Drug Name: 5-OH-DPAT Drug Info
• Synonyms: 5-OH-Dpat; CHEMBL273273; 68593-96-4; 6-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol; 6-dipropylaminotetralin-1-ol; 5-Hydroxy-2-N,N-dipropylaminotetralin; 5-Hydroxy-2-(di-n-propylamino)tetralin; (-)-5-hydroxy-2-(dipropylamino)tetralin; 6-Dipropylamino-5,6,7,8-tetrahydro-naphthalen-1-ol; GTPL128; SCHEMBL279021; AC1L58V4; 2-Dipropylamino-5-hydroxy-1,2,3,4-tetrahydronaphthalene; 5-hydroxy-2-(dipropylamino)tetralin; BDBM50020221; 5-hydroxy-N,N-dipropyl-2-aminotetralin; L000957; 1-Naphthalenol,; 6-dipropylaminotetralin-1-ol

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 172267
  CAS Number: CAS 68593-96-4
  TTD Drug ID: DMZT6JR

Molecule-Related Drug Atlas

Drug(s) Targeting Dopamine D3 receptor (D3R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cariprazine	DMJYDVK	Bipolar disorder	6A60	Approved	[4]
Pramipexole	DMNMW9R	Parkinson disease	8A00.0	Approved	[5]
Ropinirole	DMA6S1D	Parkinson disease	8A00.0	Approved	[5]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[6]
P2B-001	DM9PVHX	Parkinson disease	8A00.0	Phase 3	[7]
RP5063	DMKUE8O	Schizophrenia	6A20	Phase 2	[8]
ONC201	DMM5SCF	Endometrial cancer	2C76	Phase 2	[9]
TAK-906	DMBQD9H	Diabetic gastroparesis	DA41.00	Phase 2	[10]
GSK598809	DMGU05N	Drug abuse	6C4G.1Z	Phase 2	[11]
GSK618334	DMJPXZ4	Drug abuse	6C4G.1Z	Phase 1	[11]

Drug(s) Targeting 5-HT 1B receptor (HTR1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[12]
Eletriptan	DMW649X	Migraine	8A80	Approved	[5]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[5]
Frovatriptan	DM7RE8P	Migraine	8A80	Approved	[5]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[5]
Naratriptan	DMO50U2	Headache	8A80-8A84	Approved	[13]
Prolixin decanoate	DMMJ1IS	Schizophrenia	6A20	Approved	[5]
Eltoprazine	DMW6C81	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[14]
NXN-188	DMMBAIH	Migraine	8A80	Phase 2	[15]
[N-methyl-3H(3)]AZ-10419369	DMSCV02	Mood disorder	6A60-6E23	Phase 1	[16]

Drug(s) Targeting Dopamine D2 receptor (D2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[17]
Haloperidol	DM96SE0	Delirium		Approved	[18]
Perphenazine	DMA4MRX	Schizophrenia	6A20	Approved	[19]
Perazine	DM2AOTZ	Psychotic disorder	6A20-6A25	Approved	[20]
Domperidone	DMBDPY0	Gastrointestinal disease	DE2Z	Approved	[21]
Levodopa	DMN3E57	Parkinson disease	8A00.0	Approved	[22]
Quetiapine	DM1N62C	Anorexia nervosa cachexia	6B80	Approved	[23]
Pimozide	DMW83TP	Schizophrenia	6A20	Approved	[24]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[25]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[26]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1B receptor (HTR1B)	TTK8CXU	5HT1B_HUMAN	Antagonist	[2]
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Inhibitor	[3]
Dopamine D3 receptor (D3R)	TT4C8EA	DRD3_HUMAN	Inhibitor	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 128).
• [2] Mouse 5HT1B serotonin receptor: cloning, functional expression, and localization in motor control centers. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3020-4.
• [3] Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a... J Med Chem. 2010 Feb 11;53(3):1023-37.
• [4] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
• [7] Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.
• [11] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [12] Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
• [13] Triptans in pregnancy. Ther Drug Monit. 2008 Feb;30(1):5-9.
• [14] Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
• [15] Company report (NeurAxon)
• [16] 5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett. 2015 May 6;594:137-43.
• [17] The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
• [18] Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
• [19] CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
• [20] Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
• [21] Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
• [22] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
• [23] Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
• [24] [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
• [25] Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
• [26] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.